These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31659433)

  • 21. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
    Gonzalez-Duarte A; Ulloa-Aguirre A
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis.
    Polimanti R; Di Girolamo M; Manfellotto D; Fuciarelli M
    Amyloid; 2014 Sep; 21(3):154-62. PubMed ID: 24779883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals.
    Parcha V; Malla G; Irvin MR; Armstrong ND; Judd SE; Lange LA; Maurer MS; Levitan EB; Goyal P; Arora G; Arora P
    JAMA; 2022 Apr; 327(14):1368-1378. PubMed ID: 35377943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease-Modifying Treatments for Transthyretin Amyloidosis.
    Tushak ZJ; Cox SZ; Cei LF; Gwathmey KG; Shah KB
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e641-e647. PubMed ID: 34321398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New sequence variants in patients affected by amyloidosis show transthyretin instability by isoelectric focusing.
    Hinderhofer K; Obermaier C; Hegenbart U; Schönland S; Seidler M; Sommer-Ort I; Barth U
    Amyloid; 2019 Jun; 26(2):85-93. PubMed ID: 31074293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
    Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
    J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic
    Pathak GA; De Lillo A; Wendt FR; De Angelis F; Koller D; Cabrera Mendoza B; Jacoby D; Miller EJ; Buxbaum JN; Polimanti R
    Amyloid; 2022 Jun; 29(2):110-119. PubMed ID: 34935565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transthyretin Cardiac Amyloidosis.
    Mankad AK; Shah KB
    Curr Cardiol Rep; 2017 Aug; 19(10):97. PubMed ID: 28840452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population.
    Greve AM; Christoffersen M; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    JAMA Cardiol; 2021 Mar; 6(3):258-266. PubMed ID: 33237279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.
    Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S
    Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities.
    Cioffi CL; Raja A; Muthuraman P; Jayaraman A; Jayakumar S; Varadi A; Racz B; Petrukhin K
    J Med Chem; 2021 Jul; 64(13):9010-9041. PubMed ID: 34138572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
    Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
    Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel transgenic mouse model expressing mutant TTR gene causing oculoleptomeningeal type of ATTRm amyloidosis.
    Isoguchi A; Ueda M; Kanenawa K; Masuda T; Misumi Y; Yamashita T; Obayashi K; Ando Y
    Amyloid; 2019; 26(sup1):69. PubMed ID: 31343295
    [No Abstract]   [Full Text] [Related]  

  • 36. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population.
    Lavigne-Moreira C; Marques VD; Gonçalves MVM; de Oliveira MF; Tomaselli PJ; Nunez JC; do Nascimento OJM; Barreira AA; Marques W
    J Peripher Nerv Syst; 2018 Jun; 23(2):134-137. PubMed ID: 29520877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.
    Rapezzi C; Merlini G; Quarta CC; Riva L; Longhi S; Leone O; Salvi F; Ciliberti P; Pastorelli F; Biagini E; Coccolo F; Cooke RM; Bacchi-Reggiani L; Sangiorgi D; Ferlini A; Cavo M; Zamagni E; Fonte ML; Palladini G; Salinaro F; Musca F; Obici L; Branzi A; Perlini S
    Circulation; 2009 Sep; 120(13):1203-12. PubMed ID: 19752327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid deposition in a mouse model humanized at the transthyretin and retinol-binding protein 4 loci.
    Li X; Lyu Y; Shen J; Mu Y; Qiang L; Liu L; Araki K; Imbimbo BP; Yamamura KI; Jin S; Li Z
    Lab Invest; 2018 Apr; 98(4):512-524. PubMed ID: 29330472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
    Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
    Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical spectrum of Transthyretin amyloidogenic mutations among diverse population origins.
    De Lillo A; Pathak GA; Low A; De Angelis F; Abou Alaiwi S; Miller EJ; Fuciarelli M; Polimanti R
    Hum Genomics; 2024 Mar; 18(1):31. PubMed ID: 38523305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.